-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KxtfKCCVvm7u7MiO9fS0F8gS+/LtS/n8auvP8UqDSMjH4t2fDamLR4Um7OU6oUlN
 ALcyS+jyJfsQ/uLYD0fRxA==

<SEC-DOCUMENT>0001129928-09-000069.txt : 20090924
<SEC-HEADER>0001129928-09-000069.hdr.sgml : 20090924
<ACCEPTANCE-DATETIME>20090924123029
ACCESSION NUMBER:		0001129928-09-000069
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20090924
FILED AS OF DATE:		20090924
DATE AS OF CHANGE:		20090924

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		091084189

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6K FORM
<TEXT>
<html>
<head>
    <title>form6-k.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 5.1.2.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1"></div>
<div>
<br>
<br>&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SECURITIES AND EXCHANGE COMMISSION</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Washington, D.C. 20549</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">Form 6-K</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Report of Foreign Private Issuer</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to Rule&#160;13a-16 or 15d-16</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">of the Securities Exchange Act of 1934</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For the month of&#160;September&#160;2009</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Commission File Number 000-31062</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Translation of registrant&#8217;s name into English)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Suite&#160;210, 1167 Kensington Crescent NW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Calgary, Alberta, Canada T2N 1X7</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">(Address of principal executive offices)</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or Form&#160;40-F.</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form&#160;20-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form&#160;40-F&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if submitted solely to provide an attached annual report to security holders.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on which the registrant&#8217;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#8217;s security holders, and, if discussing a material event, has already been the subject of a Form&#160;6-K submission or other Commission filing on EDGAR.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">o</font></font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">No&#160;&#160;&#160;<font style="DISPLAY: inline;" face="Wingdings">&#254;</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If &#8220;Yes&#8221; is marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div></div>
<div id="PN" style="PAGE-BREAK-AFTER: always">
<div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
<div style="WIDTH: 100%; TEXT-ALIGN: center">
<hr style="COLOR: black" noshade size="2"></div></div>
<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div></div></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td valign="bottom" width="7%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">EXHIBIT</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">NUMBER</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="69%" style="BORDER-BOTTOM: black 4px double">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DESCRIPTION</font></div></td></tr><tr>
<td align="left" valign="top" width="7%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="69%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td valign="top" width="7%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">99.1</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="69%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">News Release Dated September 24, 2009 -&#160;Oncolytics Biotech&#174; Inc. Announces Start of US Phase 2 Melanoma Trial</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">SIGNATURES</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<tr>
<td align="left" valign="bottom" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" colspan="3" valign="top" width="39%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Registrant)</font></div></td></tr><tr>
<td align="left" valign="center" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="center" width="38%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="center" width="36%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td></tr><tr>
<td align="left" valign="top" width="38%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:&#160;&#160;September 24, 2009</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="2%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:</font></div></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;&#160;Doug Ball</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Doug Ball</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chief Financial Officer</font></div></td></tr></table></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit99.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>exhibit99.htm</title>
<!-- Licensed to: Oncolytics Biotech Inc.-->
<!-- Document Created using EDGARizer 5.1.2.0 -->
<!-- Copyright 1995 - 2009 Thomson Reuters. All rights reserved. -->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
<div>&#160;</div>
<div><img src="exhibit990.jpg" alt=""></div>
<div style="TEXT-ALIGN: right">&#160;<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;<img src="ctrc.jpg" alt=""></font></div>
<div>&#160;</div>
<div>&#160;</div>
<div>
<hr style="COLOR: black" align="left" noshade size="1" width="100%"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR IMMEDIATE RELEASE</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics Biotech<font style="DISPLAY: inline; FONT-SIZE: 10pt">&#174;</font> Inc. Announces Start of Enrolment</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in U.S. Phase 2 Melanoma Cancer Clinical Trial</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CALGARY, AB, --- September 24, 2009</font> - Oncolytics Biotech Inc. (&#8220;Oncolytics&#8221;) (TSX:ONC, NASDAQ:ONCY) announced today that the Cancer Therapy &amp; Research Center at the University of Texas Health Science Center (CTRC) has started patient enrolment in a U.S. Phase 2 clinical
trial using intravenous administration of REOLYSIN<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">&#174;</font> in combination with paclitaxel and carboplatin in patients with metastatic melanoma.&#160;&#160;The Principal Investigator is Dr. Devalingam Mahalingam, M.D., Ph.D., MRCP(UK), MRCP(I), clinical investigator in GI/thoracic oncology and drug development at the CTRC.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;We have seen some very encouraging results in our clinical trials using REOLYSIN in combination with other therapies in metastatic melanoma patients,&#8221; said Dr. Brad Thompson, President and CEO of Oncolytics.&#160;&#160;&#8220;For example, of nine evaluable melanoma patients treated intravenously in our combination REOLYSIN
and chemotherapy trials, five had stable disease or better (two partial responses and three stable disease).</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;In our local administration REOLYSIN and radiation studies, all of the evaluable melanoma patients (10) had stable disease or better in the target lesion, (three partial responses, one significant minor response and six stable disease).&#160;&#160;These results, combined with preclinical work demonstrating that <font style="DISPLAY: inline; FONT-STYLE: italic">in
vivo</font> combination treatment resulted in markedly reduced tumour growth compared to single agent treatments, provided the rationale for our collaborators to explore a Phase 2 combination study for patients with metastatic melanoma.&#8221;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;Today, few effective treatment options exist for patients with advanced malignant melanoma,&#8221; said Dr. Mahalingam.&#160;&#160;&#8220;We welcome this collaboration with Oncolytics, and are excited to have started patient enrolment for this Phase II investigator-initiated study at the CTRC.&#160;&#160;We are hopeful this novel
agent will continue to show promising results.&#8221;</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The trial (REO 020) is a single arm, open-label, Phase 2 study of REOLYSIN given intravenously with paclitaxel and carboplatin every three weeks.&#160;&#160;It is anticipated that up to 43 patients will be treated in the study.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Eligible patients include those with metastatic, malignant melanoma who have failed one or more prior therapies, or those who are not considered to be a candidate for standard, first-line treatment.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The primary objective of the Phase 2 trial is to measure the objective response rate (partial response (PR) and complete response (CR)) to the treatment combination.&#160;&#160;The secondary objectives are to assess progression-free survival (PFS) and overall survival (OS) for the treatment regimen in the study population, to assess disease
control rate (CR + PR + stable disease (SD)) and duration in the study population, and to assess the safety and tolerability of the combination treatment.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This trial is part of a broad preclinical and clinical collaboration with the CTRC that will involve up to five, open-label, Phase 2 studies exploring the use of REOLYSIN in combination with chemotherapy for various cancer indications.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Melanoma</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Cancer of the skin is the most common of cancers, probably accounting for at least half of all cancers. Melanoma accounts for less than 5% of skin cancer cases but causes a large majority of skin cancer deaths. The American Cancer Society estimates that about 68,720 new melanomas will be diagnosed in the United States during 2009, and 8,650
people will die from the condition. Unlike many other common cancers, melanoma widely occurs in younger as well as older people. Occurrence rates continue to increase with age and are highest among those in their 80s, but melanoma is not uncommon in those younger than 30, and in fact is one of the more common cancers in adolescents and young adults.&#160;&#160;&#160;For more information about melanoma, please go to <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.cancer.org</font>.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">About Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.&#160;&#160;Oncolytics&#8217; clinical program includes a variety of Phase 1/2 and Phase 2 human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation
or chemotherapy.&#160;&#160;For further information about Oncolytics, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.oncolyticsbiotech.com</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold">The Cancer Therapy &amp; Research Center (CTRC) at The University of Texas Health Science Center at San Antonio</font> is one of the nation&#8217;s leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including
Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a&#160;National Cancer Institute (NCI) Designated Cancer&#160;Center, and is one of only three in Texas. &#160;A world leader in developing new drugs to treat cancer, The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participates in the clinical and/or preclinical development
of many of the cancer drugs approved by the U.S. Food &amp; Drug Administration.&#160; For more information, visit our Web site at <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.ctrc.net</font>.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman">This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company&#8217;s expectations related to the U.S. Phase 2 combination REOLYSIN/paclitaxel and carboplatin clinical trial for patients with
metastatic melanoma, and the Company&#8217;s belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company&#8217;s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled
test, the success and timely completion of clinical studies and trials, the Company&#8217;s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company&#8217;s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">FOR FURTHER INFORMATION PLEASE CONTACT:</font></div>
<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="25%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Oncolytics Biotech Inc.</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Cathy Ward</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">210, 1167 Kensington Cr NW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary, Alberta T2N 1X7</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel: 403.670.7377</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax: 403.283.0858</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">cathy.ward@oncolytics.ca</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></td>
<td align="left" valign="top" width="26%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Equicom Group</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Nick Hurst</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">325, 300 5<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">th</font> Ave. SW</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Calgary, Alberta, T2P 3C4</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel: 403.538.4845</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax: 403.237.6916</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">nhurst@equicomgroup.com</font></font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">&#160;</div></td>
<td align="left" valign="top" width="28%">
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">The Investor Relations Group</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Erika Moran</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">11 Stone St, 3rd Floor</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">New York, NY&#160;&#160;10004</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Tel:&#160;&#160;212.825.3210</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">Fax:&#160;&#160;212.825.3229</font></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"><font style="DISPLAY: inline">emoran@investorrelationsgroup.com</font></font></div></td></tr></table></div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
<div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-30-</font></div>
<div style="DISPLAY: block; TEXT-INDENT: 0pt">
<br></div>
<br></body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>exhibit990.jpg
<TEXT>
begin 644 exhibit990.jpg
M_]C_X``02D9)1@`!`0$`>`!X``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@`!`3$!`@`0````3@``````
M``!X`````0```'@````!````4&%I;G0N3D54('8U+C`P`/_;`$,`#0D*"PH(
M#0L+"P\.#1`4(144$A(4*!T>&"$P*C(Q+RHN+30[2T`T.$<Y+2Y"64)'3E!4
M550S/UUC7%)B2U-44?_;`$,!#@\/%!$4)Q45)U$V+C9145%145%145%145%1
M45%145%145%145%145%145%145%145%145%145%145%145%14?_``!$(`%$!
M4P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/3J**9+*D,;22.$11DL3P!0`_-1S3PP+NFE2-?5F`KF;WQ!=WMT
M;32(B>WF8R3[C/`'N:;!X6N+EA+J-XQ8\D*=Q_,U/-?8=C:_M[2O^?V/]:DA
MU?3IWVQ7D1;T+8_G5%?"NEA0"LI/KO/-1W'A*P=,0O+$WKG</R-'O"T-\,",
M@Y'K2UQ<UCJV@/YUM,9;<=<=,>Z_X5MZ-K\&I8B<"*Y_N=F^A_I0I=&!LT44
M50!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%<=JUW/KNI#3;/B&,G<V>&P>6/L
M*W?$-ZUCI,CH<2/\B'T)_P#K9JMX3L1;:8+AA^\G^;GLO;_'\:AZNPS1TW3K
M?3;<10+R>68]6-7***L04444`!KE_$6AI%&;^P0QR1G<ZIQQZ@=C744C`,,$
M9!Z@TFK@9/A[5?[2L\2?Z^+`?_:]ZUZXR:(Z#XGB:(X@F/3_`&2<$?@?Z5V8
MI1?0`HHHJ@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#E/&KDFSA[$LV>_8?UKJ((UAA
M2)?NJH`_"N7\:*1+92X^0;@3^1KJ8V#QJRG*D`@U"W8QU%%%6(****`"BBB@
M#F/&T2?9+:;'SARN?8C/]*W]/=I-/MY'.6:)23[XK"\;,/L%NN1N,N0/;!_Q
M%;FFY&F6H(((B7@_05*W8%+Q'J$^G6*36^W>9`IW#/&#_A5/1M?>:?[)J`6.
M9L&-APK`]!2^-/\`D$Q?]=A_(U'+HD>I:'9RQX2Z2!=K?WN.AI.]]!FQJ\\U
MMID\\!421KN&X9''6H/#M]/J.G&>XV[_`#"ORC`QQ6"FL3'2[S3-0#+<)&P5
MFZG`Z'W]^]:G@[_D"G_KJW\A0G=@;CNL:%W8*JC)).`!6!_;-[J4[0Z1`I1#
M\T\OW?RJYXECEET2=8<D\%@!DD`\U2\'30?V<\*L/.#EF4GGM@X]*&];"+)A
M\0#+"[LV./N^6:T;(W9AS>+$LI/2+)`'XU8HJD@*NH7T&GVS3SMA1P`.K'T%
M95I>:UJ:">VCM[6`CY?-RQ:H/&L4C6=O*I8QHY#`#@9'!_SZUK:%-%/H]LT0
M`"H%('8C@U.[L!5E'B&%#('M)RO_`"S52"WXYI^D:]#J4AA:-H;@`DH>0<=<
M&M:N)TT>=XP9[<X02NQ.<Y'.?SH>@SMZP-#U:ZOM3N[><IY<6=NU<'[V*WZY
M+PK_`,AW4/HW_H=-[H1UM-<,48*VUL<'&<4ZBJ`YG^W+[3M3^S:LB>4WW9(U
MQQZ^XK?ENH(;4W,DJB$#=OSQBHM2T^#4;4PSCW5AU4^HKC]/L9KW43I$URWV
M>W9F('0X../\^M0VT,W--U+4=6OG>!4AL$.-S+EF]ASU_E6Q>K=M!BSDC27(
MYD!(QWJ2"".WA6*%`B*,`#M4E4D(P+^77;&SDNGN;1EC`)"QG)YQ3=-N-<U&
MS6YCN+1%8D8:,YX.*N^)?^0#=?0?^A"HO"?_`"`8?]YO_0C4];#+]@EZD;?;
MI8I')^7RE(`'XU4\17\^G:<)[?;O,@7YAD8P:U:P?&7_`"!E_P"NJ_R--Z(1
M?T2[EO=+AN9MOF/G.T8'!(J:_O8+"V:>=L*.@[L?052\+_\`(!MO^!?^A&J'
MC6.9K2WD0$Q(YWX[$]#_`#_.B^EP);?4=8U0B2RMXK:W_OS9.[Z8JSL\01_-
MYME+_L;67/XU/H,D,FCVWD$%50*1GH>_ZUH4)7`C@\WRE\_;YF/FV=,^U8VL
MZZ]C?1V5O`KS/CYG.%&3@5NU2U#3+345"W,0+`<..&'XTW>V@%,P:^[!_MEH
MF.=@C)!]B:ELVUD3*EVEJ8LG<Z$[CZ8%4CH-_;J19:O,H&,+)R/\_A54:UJ>
MG:BME?+'<98#<G7!/M_A4WMN,ZNBBBK$8OBFS-UI#.JY>$[QCT[_`*?RI_AF
M]%WI$8+9DA_=M_0_E6LP!!!&0:XR03>&=8,BKOM)B<*#U'I]14/1W&=I145M
M<174"S0N'1AP0:EJQ!1110`445BZ_K::=`8X65KEN`N<[/<BDW8#'UI_[7\1
MP64>2D9V,1^;&NQ48&!T%8'A?2FMHC>W`_?S#C/55///N:Z"E%=6,H:MIB:I
M;+!)(T85]V5^A_QJS:0"UM8K=6+"-`H)[XK&UO7+BPUNPTZ&-"+J-W+F-Y"N
MWT5>34VAZW_:4]W:S(L=Q;-@K@J64]&VL`P'UIV$2ZMHEMJA5W)CE7C>G4CT
M-3Z3IR:9:&WCD9QN+98<\U=K)U+5VL]<TK3EA#"^:0,Y/W0JYX%%E>X&M6/<
M^';.6;SX&DM9O[T)Q^E;%9^N:F-'TF>_:"2<1#.Q.I^I[#U/:AJX$(TBYR,Z
MQ>$=QD<_I5VQLELHV19YI5)S^]?<1]#65?ZOJ&G::VIW%K;R6JJ'=(I3O0$C
MH2,-U]JVX9!-$DB@A74,,C!P:+`$L:2QM'(H9&&""."*R1X>C@D+6-Y<6BMU
M5&R#^=:TOF>6PB*A\?*6&1GWK!L=5U2ZUZ_TPBT7[$(RSA6^<.,\#/%%D!8;
M1+F1"DNL7;*>H&!FKNGZ;::=&5MH@I/WF/+-]35RJNJW36.E7=VBAF@A>0*>
MA(!./THL@+58,?AL0W,D\&H7$+R$DE,=SG%2:1J5[?&%I@BAHP[*+:5,9'0,
MW!ZUM4-7`R/[(NO^@S>?I_A6G#&8HDC+LY4`%F/)]ZI:WJL>CV0N'C,A=UC4
M9PNXG`W-T4>YJ6T:_9RUU]F5#]U(BS$?\".,_E18"Y679Z+'::I-?K,[/+NR
MI`P,G-:E9FMZHVEK9N(C*L]RL+!5+,`03D`=>E%@-.BL&;Q#CQ#IFFPP/LNQ
M(7>6)XRNU<C&X#-;U,"MJ%FM]926K.460`%AU'.:;IEBNG62VR.SJI)W-UY.
M:MT4K`%4M6TY-4M1;R2-&`P;*]>_^-7:R-,U:2]US5M/:)52Q:-58'EMRYYI
M@7=-LET^RCM4<NJ9PS=3DYJQ)&DB,CJ&5A@@C((IU8^M:K=V%_9V]K9BY\Y9
M'=`V'(0#A>Q//0^E%@&GP[#%<&:RNI[0MU6-N/UI_P#8LS_+-JUZZ=U#!?U%
M0Z?XA74=<2SMX3]G:U,_FMD,'#!2A'8C//U%;M*R`BMH/L\"0AW<*,;G.6/U
M-4;S1DNYWF^UW44C`#]W)@#'M1K&KKIC6D8B\R6[F$,>YMJ`]<LV#C\JLV9O
M"I-X8`QZ+#GC\3U_(46`H?V/>[O^0U=;<>V<U)9Z#:6MQ]I<O<7&<^9*<\^O
MUK5H)Q19`%%%%,`JO>V<%];-!.FY&_,'U%6**`..>SU7P_</+9[I[0G)&,_F
M/ZBM&S\56,R`7`:!^^1N7\Q708K.NM$TVZYDM4#9SN3Y2?RJ+-;`2?VMIO\`
MS_6__?P5'/KFF0)N:\C;V0[C^E4/^$1T_P#YZW'_`'T/\*DA\*Z;$VYA++[.
MW'Z8H]X"A=^)Y[F46VE6[%F.`[#)/T';\:GT?PZRS"]U)O,G)W;"<@'U/J:W
M+6RMK1=MO`D0[[1R?QJQ34>X!1115`4[S3+.]ECEN(`TD60C@E67/7!'-2VU
MG;6@86\$<6XY.Q0,GW]:GHH`*@FL[>>X@N)84>:`DQ.1RA(P<?A4]%`!39(T
MEC:.1%=&!5E89!![$4ZB@"BNCZ:C*5L8/E.5&P84^PZ#\*O444`%01V=O%=R
MW20HL\P59'`Y8#IG\ZGHH`*CGACN()()E#QR*5=3T(/!%244`9=EX>TFPN4N
M+6R2*5,[6!/'&/6M2BB@!DT4<\3131K)&PPRL,@CW%5K;2[&TE\RWM8XVYP5
M'W<]<>GX5<HH`*AGMH;@Q&:,.8G$B9_A8<`_J:FHH`@DL[>6[ANI(4:>$,(W
M(Y3/7'UQ4]%%`!1110`5!#9V\$\\\,*)+.0TK@<N0,#/X5/10`5#):PR7,5P
M\8,T08(_=0<9_/`J:B@"JFGVB:@U^MN@NG38TH')7T/Y#\JM444`17-M!=1&
M*XACFC)R5D4,/R-06NF65I(7M[:.-N<$#H#U`]![#BKE%`!4,]I;W$L4DT*2
M/"=T989VGU%344`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
00`4444`%%%%`!1110!__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ctrc.jpg
<TEXT>
begin 644 ctrc.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0E^17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````<````<@$R``(````4````CH=I``0````!````I````-``+<;````G
M$``MQL```"<0061O8F4@4&AO=&]S:&]P($-3,R!7:6YD;W=S`#(P,#DZ,#8Z
M,#,@,3$Z,#0Z,C0``````Z`!``,````!__\``*`"``0````!```!7J`#``0`
M```!````,P`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```A(````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B
M95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%P"@`P$B``(1`0,1`?_=``0`
M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`ZKKW1.H4];9]9,?+L<RAK&_8Q/\`Q6QL
M.V_9K/4]2^OT]_\`Z*GC97UQRNNXF0*FT]%L8#;6=@X:X/+MX^U^JZW:^G9L
MJ]+T_P#A$&WZJ]<ZDW*HZIU#]%ZPMQB)M$^_W>D?0;4WTWM_0_F6?^"ES<+I
MV/GMJZ[4_,PZL.BC`>^NR]IM:;AEN970R[9U&QOV399_2+&?T/\`F\I.X>"9
MD)B8,>#VS'TQ)_RL9?OK*%&`AP^L9?>C/6>GJQ>W^X]2DN7S>J?6$Y/4A15=
M3B/JMIZ=>*6O+;\<#=>*OTEMGVA[LOTVY-56-8SI^-Z#_P!?4'=5ZT[(<SJ#
M[^F8S;[:WW44"P[ZJ<+T::'V4Y;7X>;=9U#(IR'X_JOV48F^C(_5GM7O5I+C
M;.I?65[<]E#[[,AN>:JJ:VUM>S'%F4*_2^U=/9C4^M531^GR<CJ-5G^DP_65
M_K.)^TOJWB79=#,S,'V1Q<*7`@OMQ_M9JIM;]HH8]F_U:WM8_P!+V7I*>C27
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MU^G_`*)]=EU7H>I1_,]22GNTERN-U/JWK=,!R+,EE[;!:QC027[[6>M?8[IV
M#7?BT?H_YC]DWX_I_P#>C]IJ57&ZU]9#T7"MJ;DYV;)RL[9763Z=+:G6=/\`
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MM=<=PQT^OD.VM=5^KL_P=-EWJO\`YM0LZSU)C!8SIEMK34RP,82'A[F9#[*7
M-NKJ;^ALQF5[MWO^TU?HO]+\VI)*?IF_J.95E/H9B.>QKF[;1O+2TL-G+:G?
MI/4;Z6W^:_/MO9ZE="">L=1#0[]F6N!=:V&DRTUD>CO#ZV^S):+?TE?\W^B_
MTJ^;$DE/TM^U,_[/D6?8G%]/HBL`619ZHK=;:UKJ1=Z6/ZGO8VK[1^AL_1)#
MJG4#8&#`?M?;;4'DN`;L<&46V_HOYC);ZEGJ5[_2_1?Z3]'\TI)*?I.OJW4W
M65,=TYX#[:JK'`NAC7U,OMR-SJF;ZZK;?LW_`!E7Z3T_\'*SJW4&O?6SIUEC
MFFYK2"YK)8/U.7OJ^AF>[]*S?7B_X3_2+YJ224_2UG5LS92ZCIUUCKJK'[7R
MS8\?T6B[V.V?:'-<VRSW_9O\)^CL3.ZMU`-;8WI[]EAKV-._U`'"TV-N8*G,
MKL;Z3&?SOH?IOTU]-:^:DDE/TB_K?4FU.<.EV^HPP6RX@^UMOL<RISG-LW^F
MS]'[+?Z1Z/IVK8!D`Q'DOE9))3__V?_M#F!0:&]T;W-H;W`@,RXP`#A"24T$
M!```````'AP"```"```<`@4`$E542%-#4T%?0U120U]C;VQO<CA"24T$)0``
M````$/S^D$RD+&NY$&2?3L*O?5DX0DE-`^T``````!`!+`````$``0$L````
M`0`!.$))300F```````.`````````````#^````X0DE-!`T```````0````>
M.$))3009```````$````'CA"24T#\P``````"0```````````0`X0DE-!`H`
M``````$``#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`+V9F
M``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@````8`
M``````$`-0````$`+0````8```````$X0DE-`_@``````'```/__________
M__________________\#Z`````#_____________________________`^@`
M````_____________________________P/H`````/__________________
M__________\#Z```.$))300(```````0`````0```D````)``````#A"24T$
M'@``````!``````X0DE-!!H``````U4````&```````````````S```!7@``
M`!``0P!4`%(`0P!?`$@`4P!#`%\`2`!?`&,`;P!L`&\`<@````$`````````
M`````````````````0`````````````!7@```#,`````````````````````
M`0`````````````````````````0`````0```````&YU;&P````"````!F)O
M=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`````````
M`$QE9G1L;VYG``````````!"=&]M;&]N9P```#,`````4F=H=&QO;F<```%>
M````!G-L:6-E<U9L3',````!3V)J8P````$```````5S;&EC90```!(````'
M<VQI8V5)1&QO;F<`````````!V=R;W5P241L;VYG``````````9O<FEG:6YE
M;G5M````#$53;&EC94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E
M;G5M````"D53;&EC951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0``
M`````%)C=#$````$`````%1O<"!L;VYG``````````!,969T;&]N9P``````
M````0G1O;6QO;F<````S`````%)G:'1L;VYG```!7@````-U<FQ415A4````
M`0```````&YU;&Q415A4`````0```````$US9V5415A4`````0``````!F%L
M=%1A9U1%6%0````!```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL
M5&5X=%1%6%0````!```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z
M06QI9VX````'9&5F875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E
M<G1!;&EG;@````=D969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI
M8V5"1T-O;&]R5'EP90````!.;VYE````"71O<$]U='-E=&QO;F<`````````
M"FQE9G1/=71S971L;VYG``````````QB;W1T;VU/=71S971L;VYG````````
M``MR:6=H=$]U='-E=&QO;F<``````#A"24T$*```````#`````$_\```````
M`#A"24T$$0```````0$`.$))3004```````$`````3A"24T$#``````(9```
M``$```"@````%P```>```"L@```(2``8``'_V/_@`!!*1DE&``$"``!(`$@`
M`/_M``Q!9&]B95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`%P"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`ZKKW1.H4];9]9,?+L<RA
MK&_8Q/\`Q6QL.V_9K/4]2^OT]_\`Z*GC97UQRNNXF0*FT]%L8#;6=@X:X/+M
MX^U^JZW:^G9LJ]+T_P#A$&WZJ]<ZDW*HZIU#]%ZPMQB)M$^_W>D?0;4WTWM_
M0_F6?^"ES<+IV/GMJZ[4_,PZL.BC`>^NR]IM:;AEN970R[9U&QOV399_2+&?
MT/\`F\I.X>"9D)B8,>#VS'TQ)_RL9?OK*%&`AP^L9?>C/6>GJQ>W^X]2DN7S
M>J?6$Y/4A15=3B/JMIZ=>*6O+;\<#=>*OTEMGVA[LOTVY-56-8SI^-Z#_P!?
M4'=5ZT[(<SJ#[^F8S;[:WW44"P[ZJ<+T::'V4Y;7X>;=9U#(IR'X_JOV48F^
MC(_5GM7O5I+C;.I?65[<]E#[[,AN>:JJ:VUM>S'%F4*_2^U=/9C4^M531^GR
M<CJ-5G^DP_65_K.)^TOJWB79=#,S,'V1Q<*7`@OMQ_M9JIM;]HH8]F_U:WM8
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ML;-:YKV6XFVOU^G_`*)]=EU7H>I1_,]22GNTERN-U/JWK=,!R+,EE[;!:QC0
M27[[6>M?8[IV#7?BT?H_YC]DWX_I_P#>C]IJ57&ZU]9#T7"MJ;DYV;)RL[97
M63Z=+:G6=/\`TN-TMM5N4^W:STZ<G*J_3^E]I]-)3VB2Y"SJ?UD9=G/<;VXK
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MO[7SP]P/3;H%M=<=PQT^OD.VM=5^KL_P=-EWJO\`YM0LZSU)C!8SIEMK34RP
M,82'A[F9#[*7-NKJ;^ALQF5[MWO^TU?HO]+\VI)*?IF_J.95E/H9B.>QKF[;
M1O+2TL-G+:G?I/4;Z6W^:_/MO9ZE="">L=1#0[]F6N!=:V&DRTUD>CO#ZV^S
M):+?TE?\W^B_TJ^;$DE/TM^U,_[/D6?8G%]/HBL`619ZHK=;:UKJ1=Z6/ZGO
M8VK[1^AL_1)#JG4#8&#`?M?;;4'DN`;L<&46V_HOYC);ZEGJ5[_2_1?Z3]'\
MTI)*?I.OJW4W65,=TYX#[:JK'`NAC7U,OMR-SJF;ZZK;?LW_`!E7Z3T_\'*S
MJW4&O?6SIUECFFYK2"YK)8/U.7OJ^AF>[]*S?7B_X3_2+YJ224_2UG5LS92Z
MCIUUCKJK'[7RS8\?T6B[V.V?:'-<VRSW_9O\)^CL3.ZMU`-;8WI[]EAKV-._
MU`'"TV-N8*G,KL;Z3&?SOH?IOTU]-:^:DDE/TB_K?4FU.<.EV^HPP6RX@^UM
MOL<RISG-LW^FS]'[+?Z1Z/IVK8!D`Q'DOE9))3__V3A"24T$(0``````50``
M``$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`,P````$`.$))300&
M```````'``@````!`0#_X1`,:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP
M+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.
M5&-Z:V,Y9"(_/B`\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O
M(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`T+C$M8S`S-B`T-BXR-S8W,C`L
M($UO;B!&96(@,3D@,C`P-R`R,CHT,#HP."`@("`@("`@(CX@/')D9CI21$8@
M>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS
M>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@>&UL
M;G,Z9&,](FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN
M<SIX87`](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.GAA
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS
M=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U
M<F-E4F5F(R(@>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!H;W1O<VAO<"\Q+C`O(B!X;6QN<SIT:69F/2)H='1P.B\O;G,N861O8F4N
M8V]M+W1I9F8O,2XP+R(@>&UL;G,Z97AI9CTB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]E>&EF+S$N,"\B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@>&%P.D-R96%T
M;W)4;V]L/2)!9&]B92!0:&]T;W-H;W`@0U,S(%=I;F1O=W,B('AA<#I#<F5A
M=&5$871E/2(R,#`Y+3`V+3`S5#$Q.C`T.C(T+3`U.C`P(B!X87`Z36]D:69Y
M1&%T93TB,C`P.2TP-BTP,U0Q,3HP-#HR-"TP-3HP,"(@>&%P.DUE=&%D871A
M1&%T93TB,C`P.2TP-BTP,U0Q,3HP-#HR-"TP-3HP,"(@>&%P34TZ1&]C=6UE
M;G1)1#TB=75I9#I#0S0W1C1&,#4W-3!$13$Q0C`X.$(Y135&0CE$-3=&-"(@
M>&%P34TZ26YS=&%N8V5)1#TB=75I9#I#1#0W1C1&,#4W-3!$13$Q0C`X.$(Y
M135&0CE$-3=&-"(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S:&]P
M.DAI<W1O<GD](B(@=&EF9CI/<FEE;G1A=&EO;CTB,2(@=&EF9CI84F5S;VQU
M=&EO;CTB,S`P,#`P,"\Q,#`P,"(@=&EF9CI94F5S;VQU=&EO;CTB,S`P,#`P
M,"\Q,#`P,"(@=&EF9CI297-O;'5T:6]N56YI=#TB,B(@=&EF9CI.871I=F5$
M:6=E<W0](C(U-BPR-3<L,C4X+#(U.2PR-C(L,C<T+#(W-RPR.#0L-3,P+#4S
M,2PR.#(L,C@S+#(Y-BPS,#$L,S$X+#,Q.2PU,CDL-3,R+#,P-BPR-S`L,C<Q
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M-BPT,C`Q-BPP+#(L-"PU+#8L-RPX+#DL,3`L,3$L,3(L,3,L,30L,34L,38L
M,3<L,3@L,C`L,C(L,C,L,C0L,C4L,C8L,C<L,C@L,S`[0C!&1#,P,3DT,S!"
M1C`T-C1".4(U,3!!,#`V,T1!,4(B/B`\9&,Z=&ET;&4^(#QR9&8Z06QT/B`\
M<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E542%-#4T%?0U120U]C;VQO
M<CPO<F1F.FQI/B`\+W)D9CI!;'0^(#PO9&,Z=&ET;&4^(#QX87!-33I$97)I
M=F5D1G)O;2!S=%)E9CII;G-T86YC94E$/2)U=6ED.D1&03=&1C-"0D,Q-$1%
M,3%!0S0V1C0W0S$X-$4X0S4Y(B!S=%)E9CID;V-U;65N=$E$/2)U=6ED.D1%
M03=&1C-"0D,Q-$1%,3%!0S0V1C0W0S$X-$4X0S4Y(B\^(#PO<F1F.D1E<V-R
M:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_[@`.061O8F4`9$`````!
M_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0$!`0$"`@$"`@,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P/_
MP``1"``S`5X#`1$``A$!`Q$!_]T`!``L_\0!H@````8"`P$`````````````
M!P@&!00)`PH"`0`+`0``!@,!`0$````````````&!00#!P((`0D`"@L0``(!
M`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3(@`(,11!,B,5"5%"%F$D,Q=2<8$8
M8I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$5'-%1C='8RA55E<:LL+2XO)D@W23
MA&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI:G9W>'EZA8:'B(F*E)66EYB9FJ2E
MIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8V=KDY>;GZ.GJ]/7V]_CY^A$``@$#
M`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B$T%1!S)A%'$(0H$CD152H6(6,PFQ
M),'10W+P%^&"-"624QAC1/&BLB8U&50V160G"G.#DT9TPM+B\E5E=58WA(6C
ML\/3X_,I&I2DM,34Y/25I;7%U>7U*$=79CAVAI:FML;6YO9G=X>7I[?'U^?W
M2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!
M``(1`Q$`/P#9:_GM=]=_?'[X/9#<'1-<FW5WGOG"];=C;UHI*B+=&T-E;KQN
M8C:KVM/$53&UV;RU+3XR2NOYJ2.MO!IF9)8G[=5:4!N'4&?>%YBYCY;]OY[G
MEY_#,TZPS2"H>.)U:I0_A+$!"W$!NVC$,NL-_)J^7/>_67S;Z'V,.PNTMR=-
M;DR&=VOO?KJ?>&Y<IL3";7R.W<FL^^Z_;];D*C`X/%=>U<4&6JZ\QPI245-,
M7=4+`N[K-96%C=7][<1PVD*,\DCL%1$459W=B`JJ!DD@#SZQ3^[SS-SB_N7R
MGRWMDNX7MK>S_3BTB,LH8R@JI2!2061B)*A"P5#3%>MZ+L[Y+]&=0]/[N[XW
MGV3M:'J_96-.1S&Y,3EZ#.4\SR.L&/Q.*7%U%2<IG<U72)345)$6FJ:B1447
M/M/R8D7N%?6.W\EWEON4UPU$,$J2IZEF=&95515F8FB@$GKHQSO,WMOM]_N7
M/%I<;9!;)J<7$3Q/Z!51U5F=F(55`J6('5)7QH_X4/\`4'>'=.S>GMY]"[RZ
MSB[&[!H]C[0WK'O'`;DP],VXLR,5M*JWC03T6WZG!-6R5%/'5_:R9&.GFD.E
MGC&OWDGS3]VO>M@V*]WJQY@ANC;6QEDB\-T8Z%U2",@N'I0E=00L!D`XZQ;Y
M/^]1L',G,%CL-_R[-:?570ABE$JR+WOIC,@*IHK4:M+.%-:5'6Q5[QHZRKZ]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]#>\[,ZOZZ[FV3F^N.U
M]E;;["V'N..GBSFT]V8JDS.#R2T=7!7T;U%#61R1&:BKZ6*>&0`20S1JZ%64
M$;!(-0<]%VZ[3MF^6$^V;Q8Q7.WR4U1R*&4T(8&A\PP!!X@@$$$=45_,SX%?
M'_X=]?OOOXL]68WJ['=C;DI-J]OOB<AN/,SU^&2EFRVVL52UFXLOFI]M[2;-
MX]Y:VAHFIJ2NJ_M&G1_MX0N&?WW+OFB/VZV#]W[@\?+3[AX=[&F/%U(7M_$8
M9\)'1ZH3I9VC+5*KUE=_=[>V/M+RI[I\W;AMO*D$?.,FV![29FDD,2I(%N5@
M65W$;R)(A+(`VA&`P>B1].?&O=WRUQO;O16U:.G7$=@]6;@P^<W-D%E7;>S\
MY2R4FY^M]Q9B>GAJ)2]-V%MO'@1P1RU<E*:CQH55[0=_=_\`,O,O)7WC>6N;
M=AVZ6?8+:&9-S*4"K:31LN22%,K2*OA(35B&.%5F&4G]X=RMRUSW]VGFCDW?
M]QB@W^ZF@?;!)4LUW!(K<`&<1+&6\9P**"HRS*K`S\:_^$^/RQ@^1VS8._LG
MM/9W3.U<A2;NSG876>^*;-9G.38#(TU7C]L;/I*FAQF?PN;RM7&C'(5=#'!0
MTRO(ADG6.%OHCYI^\?R>_+%ZW+L4TV]S*8UAGB*JH<$&20@LC*HKV*Y+&@-%
M)8?-OR=]UKG2#FVP_K-/%!L4+"1YH)0S,5(I'$#2178_C:-545;+`(VZB!8`
M<\"W))/']2;DGW@QUT'Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=?_1V7.[/YTG2?5'<>8ZXV[L+<':^T]M7QN?["VAN##4]*=S03R1Y+&[;QV2
MBCI=Q8W&!1')6BNIXY*D.L0DC42M,&S>SN\[KM$.X7%]':W4F5BD5B=!&"Y&
M4)XA=)(%*T..E*VS,M2:'JI7^9__`#,.[^P^R-B;<Z6W-NSJ/IZFV7LOL[:E
M9M_+SX?<V_Y=Z[?BKFR.[I\94O`*/;=9+5XG^$K+44J5M)422M,QB$(SY+]N
MMDM['<8]_L;>]O3+)#*DJ+)$H1J4574@ZP`^H@$JR@`9KS`^]O[V>YO+GN7'
MR?RYO%YLEAM8BFBEM)Y()KEY8E<2M+$R-X::FC6('3J5V?4Q4)9[_(Y^2>Z.
M\>H.YL#V$V/R&\]A[\Q%?4[LH]J8';3Y[;^Z<#IQD>:JMMX?#XS+9C$5NWZP
M/-,K5?V\\7D9AI/N)N?/;OE'D+<8GY.Y=LMMLKX%Y8[:)(@\R$`R,J`5)4J`
M3_":4ZR0^ZO[[^XGO1RKO-K[F<V[AO.][//&D,]U(\K+:S*2D2NU0=$D<K'.
MJCC57!ZA=1]R?S!OYH%)NSO;XK?(?KSX,_"NFWSO39'Q\W94=`83Y"]]?);'
M]=[GRVRMP]RYB+L#=&'Z^ZRZDW'N?!U2;;QT&-KLY7T,!JZBII4FAC(%ZRFZ
ML^^*^!^6>UM@YS;GS"["Z:[9W[A]YY.CV=V9TUL;<?65'O7K5<9A7P68WYU]
MG=P[LHMJ=BMF'R$==3XG)56):GCIY(2C/)&GNO=*KJGY(]%=X[L[EV-U)V?M
M??N[OCWOL]9=TX'`5<M17]=[\6D^];;6?22")$KTA5U8Q-+$LT,L1;RPRHGN
MO=3]D]_=+=C]F=N=-;%[+VEN?M7H6KVK0]Q[`Q64BGW1UU4[XP2;FV@NYL4=
M-111;BP3BII9+-%*@(#:E8#W7NIFU>[NH][8?LC<6V.Q-JY3`=/;QWKL#M+.
M+E:>EQ&P=X=<1QS;\P>Z,E7-2T>)J=I0RJ]<\KB*GC]3.%!(]U[HKO0O\T/^
M7Y\G^T8>EN@_E;U1V;V;74>=R&!VO@,K6I+O+'[86:7<.0Z^R>2Q]!A>Q:'"
MTU/)/4S8*IR,<5/&TS,(E9Q[KW2$'\Y'^5ZW98Z=7YK=*OV<=_#JT;-CR^3D
MRY[";<@V>-IZ$Q+0?Q;^\Q^RT:](GXO;GW[KW2W[K_FE?R\/C?VYD>B.^OE]
MTIU%VSADV]+F]G;]W5'MRJP<&Z\?2Y;;M3G,CD((L+AJ3*XRMBGBEJJF*/Q.
M&+`>_=>Z/5BLKB\]B\;G,'DJ#,X7,T%'E</F,564^1Q>5Q>1IXZS'Y+&Y"CD
MFI*Z@KJ29)89HG:.6-@RDJ0??NO=:_G\Q'>/\UGX@[4P/;>T/GET+G]K]F_+
M;HSHC:_7^4^"E)#5['VQ\BNZ<1USAJZMWDOR,J)-UY'KK%[CAD>^/H1F9*4Z
MC2>3T>Z]U8YUW6][?$;K[N/M[^8+\V^HNU>K-L8C#9R#>6*^.$/QNQ'5N)QT
M^0I]PY+<U72]M]KC<E+FI,A0K'=*0T34[6,OF]'NO=&M[+[@ZQZ;V[B-V]H[
MUP>R-MY_>&R-@8;,YRH:GHLCO/LG<F,V?L3;M-(D<A?);GW-F*6BI5L`\TZ@
MD#GW[KW16_D;_,Y^`GQ%[#BZF^2GRGZLZ>[(GVWC-WQ;.W?DZZGS3;9S-7DJ
M'%YK[>DQ]6%H:ZLQ%3'&Q8:FA;CCW[KW67L?^9C\"NHNI>G.]NR_E%U?L[J+
MY!4=7D.EM]YC(U\6%['HJ&C@R%94[::+'2U55%2T55'*Y:--*."??NO=&&Z)
M^0O1GR>Z\QW;/QW[;Z_[JZVRE55X^CWIUONC$[KP/\3QYC&1Q%568FIJ%Q^:
MQQF05-'4"*JIRX$D:DCW[KW4'KOY*=#]L]H]T]*=;]H[4WCVK\=<CM;$=V[&
MPU9)/G.N<CO7%5&:VO2Y^%X8XEDRV.HY70PO*J-$\<A212@]U[HO/=?\T?\`
MEY_&_MROZ)[[^7G2O47;&)BV]49G9^_MTQ[<J<)3;KH:?);>J\YDLA#%A,+1
MY7'U4<T<U54Q1^-P2P'OW7NC+XCO_I;<':L'2&#[+VGENUJSJG%=YX_95!DX
MZK*Y;I[.9R7;6+['PK1!J+-;3JL[%]L*NDEFC21X]6D2QE_=>ZG[6[JZIWMV
M5V?T]M'?6`W'V9TK%LR7MC9^)J6K,IU^>P\569W9--NCQ1M2XS(;DPE#)64U
M,\GW#4FF8H(Y(V;W7N@^^2GR^^-/P_V[MS='R2[?VOU7C-XYN7;FSX,Q_$LE
MG]W9NGHI<E6X_:NT]NX_,[JW'+C,;"U36&BHITHZ<>6<QIZO?NO=";U-VWUG
MWOUOL_M_IO?&W.R>L-_XB+/;-WQM+(PY;;VX<3+)+`*S'5T!*2".I@DBD0Z9
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M86J2:2145#`Y/`O[]U[KGT-W[TW\H.J-J=Y=`=A;?[4ZEWQ%DYMJ;YVO-//A
MLRF&S.0V]E13FJ@I:J.7'YO$U--*DL:.DL+`CW[KW15^J/YKO\M[O#M3'](=
M6?,[H;=G;68R]=M_![!@WK28S<.X=P8RIFHZ[`;;I,VF,7<><@J::131T+5%
M2VAB$(!/OW7NAD^3?S7^*7PUQ>VLK\F^]-B=1+O2NJ,;LS$[AKZBKW7O&LHD
MCER$>TME8*ERV[]RIBXI4:KDH:&>.D61#,R!EO[KW6'9?S@^(_8O6G5'<6QO
MD#UKNGK/O'LS$],=5;PPV=2KQF\.V\Y4Y2CQO6U&J1_=T6]9:O"5<4F.JXZ>
MJ@E@=941A;W[KW0Q;K[>ZSV-OKJ[K/=V],'@-_=UY'=.)ZHVKD:EHLMOO);(
MVQ5[SW91X"`(PJI\#M6@FKJ@$KH@C+<_3W[KW2*^4WR/ZY^(7QT[E^3?;555
M4O7G26P,_O[<B8Z*.?*Y*'#TK/0;?PE/+)##49[<N5D@QU!&[QQR5E5$K.BD
ML/=>ZK.V'US_`#I/D)LG!][[E^8/1/PFW)O#%P;LVM\0\!\4,-W]MK8>&R<"
MY3;NS>[NX-W]C;9WKN_?$=!/%3Y^?;$6WJ"CK!*M&LZ*KM[KW1T-]_,7KOX9
M="=/;T_F/=U=$])[^W938?:&ZL]MZMW30]4;@[:CP-3EMP8WK=-QTU9NK^"S
M18RJJJ2&NU5,=,EI'9E+'W7NH>Q/YF?P)[-Z3[7^1VP_E)U;N7HSHVLH,?VY
MV=09.M&U]@UF33'24$&X*NIQ\$E.]4F6IBNE''[R\^_=>Z,KO+N_J/KW:.T-
M^[R[#VO@=E;_`-S]=[,V3NBJR44F$W3N?MO.8K;?6F(PF0I?N*>OJ-[9S.4=
M-CV0F.=ZA+-9K^_=>Z)'V?\`SD/Y7W2_8F\NI>U/FMTKL;LCKW<5=M'>>S\]
MF,E39C;^YL8P2OPE;$F*DC-?3,?4D;/_`(7`/OW7NE9NC^:O_+KV5TUUC\A=
MU?+CJ+!]+=SYC=.W^K.Q*W+5RX#>^:V165&/W;C<(Z8YZJ:JP%92R1U"M$F@
MK^18GW7NG_;?\R[X&;O^/&__`)9;;^475V5^.'5FY:39_87<$&3K4V?M/<]?
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M.[M]=?[9J\%'VE@=S9/;.;1<OGLMNO)8W%XZ)ZG`';U#N#/U;4$-;15<T,4E
MF=B6]Q9<^Z7,'[YW'<=N\.*TGD#>$RAAVJ$4L<-J*JNHJP!(X=0A[H^Q/MQ[
MNWD6Z<V;5+^^(X!"EQ#*\<BQAF95T]T349V(+Q,14@&F.C=]*_#KJ[XY=4;D
MZFZ9GW'M[!;@VC+@)5R.8;(JV>EQ>0Q]7OJI1*>F$F[<U+6K)75*A5D6GABB
MCBBACC4$;UO6X;_N$VY;E-JN'\AA54<%09HH_:34DDDGH8<A\A\M^V_+5CRK
MRM9>#ML-26-#)+(U-4LS@#7(U!4T`4`(BJBJH(Q_(6[`PM;_`"X^FOCODHZ+
M;/>?PJAS/Q2^1_5<DL<.YNN>T>IMPYG;LQSN+;14Q4>^\/14^>QM9I-/D*6O
MUQ.Y60*5=#'HY7S3^8NQ_BM\5ODYWUCLM@=Y;HZ'VG64%'L;#Y6BRN8R'=>Y
MZ'%X_IWJO)XS'U$U=C=Q=A[SW;@J.EI942HDBRD4JH4=2?=>ZUO/@!N#=7P1
M^7'P.EWK\7_EQT/BOE=T_6?#WYL]N_(KKWKC9^Q^V_G%N+=.[_D9U%VMB\UL
M/M'?-9E]T[[[4W;V'MFGDRE+1NV.S.+IE9VACCC]U[H3<AU=VEU]\\_YK_\`
M,;^,&W<WN[OWXF_,'JK$]I]1X"L>.H^4WPUS'P:^+>=[>Z0AQKR)15O8NT*F
M#^^&PYV!D3<./>AL\63D4>Z]T`&;[;V!W;_*R^9/<&V-SKG_`(<]W?SY\5NC
MOW>&/DR6/QV2^%'8/R<Z!JNSJW-LBTM?0;7KMNUT-+GXIU18\;)5PU*B,2K[
M]U[K<7HL-L.DHMD+CL5M&FQV!AIZ3K=:*APT-%AJ>3`5-!2TVR!!$L&.A?:P
MF@C2@T*<?K0#PZA[]U[K7@_DLT/S\DZPAJ-M5'PQ;X:#YM?/=LM2;BP?=$GR
M@_A8^8G?J9YL;EZ#-#JM<G_?-&:C,M'XQBPBR?OW?W[KW16_DC\D?DK\7?G;
M_/M[+Z8^+G5'R-ZOH-B_R[X>_,KV7OW<>/CZDV=D_CEN3!UO8-9T[MCJK?V6
M[KZXVCM_*5^8W504=?B\C%B<?)]O%4ZW:'W7NMA+^6MT-M_XQ?`?XE=$;5[5
MI.\=M]>=(;)QN%[=QC1G!=@X[(XU<]3;EVND59D(Z?9U<F6OAH143^#%"GC\
MCZ=1]U[HH/\`/,_[)<^._P#XTE_ET?\`P5O77OW7NE1_/KU?\,[_`,P+1;7_
M`*`\OX]7Z?)_',%X]=N=&NVJW-KVY]^Z]U7%_,@I_P":G'TI\:V^4>6_E]U?
M2H^??\NG^,P=![>^1N/[1:M/RUZC_N^<75=A[GR>TTI5R_A-8)86=J;6(B'T
MGW[KW0R=B4OS@JOYU?S"7X4U7Q,I<L/@1\)AOW_9J\-V[F,7+2'M3Y7MMI=H
MIU-F</4PS+5)5&N^],BLH@\0!#D^Z]THOYG6;^0.U/G/_)#S74W6'67<'R`Q
MNX/F^\76V<['RG3_`%IN+-M\098]X18_?\VR.QLKM^AHX&JY\4M1B*EJB2.&
M&=X`[SQ^Z]T'_P#+O^1>W>IOBW_-&_FR=YKLKK7=^^^SMU[Y[Z^)6PX<OC8_
MC+V1\8.M,9U,>C=UR9[%X3(;@^0/8.7PE+/E\M'C:2DSM7E\?+1+-3O#/+[K
MW1"?ASOSLOX9?(3^7QW]VW\1_EET?N_Y%93L[X__`,R_O?NSKGKO:O6'8_<G
MS4[3/=74&ZZ#<>V^T]X9Z=.MODIF)-I86JRV,QW@VGFO$[0-&E,_NO='+7<7
MRZA_FT_SH-A?%SXI](?)"E[&Z\_E][>WSFN_.]_]$^P.O)*[X\;_`,9AAN/9
MU'U-VAG>T=L9BDKZR7(4=%]C*(J40`L:C7%[KW2C^37PRW7_`"VOY6GQ;^0/
M6N_<7NSY7?R;.GJC=^&WYEJ3*4&V.ZNK#B12_(SX\;CI:>JDR\'5.^ML2M_`
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M/Y,>`QG7F_\`Y?=2_);(;PW9_-4Z^W/@,-\J>W^T=VY3=>;^072D=1G*SXX]
MQ='C)I28S:OQRS>!R53%3[=PM)34^W=Q1UU)7*U2(99/=>Z!W_A/K1?/QOA-
M\,ZK*U'PSF^&"X#M8X^EH\)W0GREBQ/^DCM)L(:C+U.9FZI;))O,H]5HHTC;
M'%A'IGLWOW7NA([WV5\G/Y5<?S;^8_3,?0ORF^#W97978'S,^4W0W:0K=@_(
MG9%=-@]OT/;E7TIV]3MG^NNT,/C,1LXUF-VINK%XZHA:`8VCR5S$A]U[H/>Y
M\U\M-]_SN,5NKX.3_&ZAW%NG^3GU?N/.+\M,!VG6;?.Q\Y\LM_93$0XK&]69
MC%9FAW2F0GA-0E7))`D2LH'D`;W[KW1A_P"<-W!VMM?X,=8_%8;;S>]_DY\\
M-P;,^-6ZMD_%K&SY#<U9L2LP)W=\U=T=*X7>>5PLSXS!=(X#<E/BVS&1HOMY
M\I0_<U*N23[KW03_`,J#MZ+J[YI_,;X<#XY=V_$KIWN.'$?-GXB]2=^[.VEL
M3/8ZFJ*#:W5WRKVALW&[.WYO_;DFU<-V51X3<='24U:L].=SUC24\<:K++[K
MW5,/QPS7>_=OP3_EF?`WM?K'J'H;XG?(CY>[XR'6OSRJNPMP;SWY%V%TA\V>
MP^Z\/T]@=BTO6VW\3T9WSW'D=J9'";5RU;N?(8^MH(:M(B]?/'CS[KW6PC\:
M(]N9;^=S_,SJNU(J"J[HVGT/\,*'XQ_QY$DRN(^)N<V?NJK[&JNMONQY:?"Y
M?Y(+EHMRR4E@U93X])S;PZO=>Z2/\[.@W11["_E^P?'F'JS&=LU'\X'XEUFU
MVWI09%NN_P#2=78OM"JCKNRZ/8\U!N6JIZIY4EKC3RQY"565M?(/OW7N@'[*
MA_F#Q?S5OY-I^:V1^&U=@#V3\UAL-?BYAN[<7F(\Z/AMO_\`BC;N?MC/9BBF
MQ+8WB!:-8YA/RY*<>_=>Z/M_/#ZNWYV]_*Q^6FV>L]NUV\=XX';>PNV*#9F-
MBDJ:[>6/Z+[<Z_[JW'M.EHH4EGR53N';6P:REBI8T>6IEE6)%=F"GW7NC^]!
M=\]5_)OICKGO[I?=^(WMU?VEM3%;OVIN/$5D-3338_)TJ3R4=:(V+X_,8>H+
MTM?1S".IH:R&6"9$EC=![KW5./\`-CW'V)OGN/\`DW[C^(^Y^D-R=A9?YO=C
MS]8[G['JLYNSI.OGI_B!\CH,M49NKZSRD.;R5'%C*:MC@;'U0*5Z1ZSH5Q[]
MU[K!_-3QOR./\D_Y=8_Y?Q?'O(]HUQV+29:#X[8K?M#U9D-G5G??55-BJ.7'
M]F5V2W*^4GQTLL60#S-3R7_;`4D#W7NJ]/ES-N7X,2]#_P`L#?T^7R'2&=_F
M.?R]^XOY:&_\D*O(1S=-XCYJ]397M?X@9[.5#SS'=?Q<J,E#4;9-3+++DM@5
MM*@?R8J93[KW5NW\UJ"!>V_Y/$BPQ*[_`,V?JIF<1H'8GXS_`"J:[,!<G4@/
M/Y`_I[]U[H#OYM5)WDWSU_DL4_QC/3M)W.>W_FJVSF[UQ^[ZWJ>-!\2-QON%
MMRT/7U7CMURRMMX57V1I9D"UQB:6\0<'W7NF'^<I'\DL?_)2[7;Y$TO164[^
M@[C^*4];1]$#?&W>H,O51_./HR39=%12[_\`X[N[$"MQZT<&2GF%8(9S++#&
MZ!(O?NO=`_U[V#\Q.ZOYFW>W<VY?C'\=^M/FA\(>@<)T9UW\/,?WSGJ6H^2?
M3_RC[BZCS>6^4NZ?E17](8V#,]`=98C9F4.&QF-V9D\K0;EH<A35L5)65-)#
M-[KW7__3W^/?NO=>]^Z]U[W[KW5?WR/_`)6_P5^5W9,7<O<?1R2]P#$1;>K>
MUNM.Q.UNBNQMP8"GCC@IL)N[>71^^.O,_O/%4E-$L,$&6GK4IX0$B")Q[]U[
MI2[$_EO_``=ZQZJV?TEL#XY;$VGUAL?N;9WR'Q.U\.V>IURO=^P<E1YG:79V
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M8NMK\QCH\?O_`*MW1C]Y["W''-A,CC*J6HV]N;%4]4D,DCTTS1Z)HY(RR'W7
MNI?=?2O5_P`B^JM\=(=T[1H]^=5]D863;N]]GY"KRE!19_"RSP5,E!45F%KL
M9E:>-IZ9&U03Q/=?U6O[]U[K!VYT;U3WOM;![)[9V?1[RVOMK?77G9>#Q%96
MY>AAQ^^.J-V8C?/7V?CFP^0QU7)/MO=>"I*R.*21Z>9H0DT<D99&]U[HJOR/
M_E:_!+Y;=J-W;W[T=)O/M.3:6$V)/O#&]I=S[`KZK:6VZ[,9/!82MINM^Q-H
MXVMIL97[@K)8FE@>0-4-=B+`>Z]T+VSOA9\9=A)\:EVQUA!2R?#ZDWM0_'&L
MR.ZM\[AR76E-V/MRKVCO9:7*[BW-E<EN*3/[<KY:623,2Y"2-'O&R,%8>Z]T
MT[R^!OQ'[`W#V]NC=O2FW\IEN_MT='[U[J5,KNK&XCL[=GQPS=%N+IG<.\=N
MXK/4.WLSE=G93&4A,LM*6R4%'3T]?]U3P0Q)[KW0P]X]%]3?)/K#<G3/>&R\
M?V!UGNV3!S9[:^2J<G0P5=5MG<.*W9MZN@R.$KL9F,;D,)N3!TE;2U%+40SP
MU%.CJX(]^Z]UQVAT3U-L+M3M[N[:.S:+#=I]]0==TO;N\(:W+U%=O6#J?!9'
M;77J5]+6Y"IQE'_=K!Y:HIXC204YE64F8R,`P]U[IR[BZ@ZX[_ZLW]TIV_M>
MEWKU=VAM?+;+WYM*MK,GCZ3<.V,Y3/1Y7%5%;A:[&Y:EBJZ9RIDIZB&9;W5P
M>??NO=+W'T%'BL?0XO'P+34&-HZ:@H:9&=EIZ.CA2GIH%:1GD98H8U4%B20.
M23[]U[HFWR+_`)=_P_\`E9OO$]H]U]3U.7[)Q&T*GKQ=_;*[([6Z>WCE^O*R
MNER=1U_NS<?3N^=A9;>FQFR%1+,N(R\M;CXY9Y62)3+(6]U[I=])_#/XN?&W
M=N>WMT!TILOIO.;HV)L7K;<4'7%+5[3VUFMI=9QU]/L2FR.R</64NRZK,[;H
MLE-2P99L><N:-A3O4O`B1K[KW2^W+T/U+O#N+J_O_<FS*+*]P=+[>["VIUCO
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MTF=]]E;=V3!UQB-WX_LGMWK_`"M/L>FSN3W-3[;F/6N_MGT]=CXL]F:FJ`J(
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M_@;\3_E]5;&RW?\`U-3[NW9UD*V/KWL7![MW[UOVQLVER<:19;';?[:ZQW3L
MWLK'X?,+&IK:),K]I6.JO-&[J&'NO=1-E_R^_ASUYUSU?U/LWHS;N%V)TWW?
MB?DGU_BH\ONVKKL?WWA9,C+0]L9S<F0W#5[HWMO4R96<SUF<K<B]7J'G\FA-
M/NO=#EO3H_JOL/L;IWMK>>SZ+.]B=`97>6;Z?W/45F5@J]DY3L':%;L+>-70
M4U%7TV.K7SFT<C/12+60U*(DA:,)(`X]U[H5O?NO=54[[_DD_P`L/L3>F[]\
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M)M_>&2IA%5+/3%:IF:(NJ,ONO=`Y\KO@G\4_F]1]?T7R?ZIC[,CZLS&:S_7M
M0F\^PMCY+:V7W'BX\)G*S&Y?KK=NT<KJR>)C%/*LDSQF.XTBYO[KW2#V=_+&
M^#VQ.C-[_&K;W2-^DNQM^;1[-WEL;/\`9/;N\8,QO?8>;VEN3:.;_CF\-_9W
M<V/_`(+G-BXJICIJ6M@I'DI`9(G#RA_=>Z,AN7X^]-[O[IZR^1.X-B8RM[LZ
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M:H:42"BJ$<O;U'W7NA2^0OS`?I'NWI;HW';$P>;S_<5%7Y/&9[L#M7;O3.UJ
M\8[=.U]LS[*Z[S.Y\7DZ3LSN6:+<C9*':M.]%4RXRCDF$X+(C>Z]U-Z]^3^^
MNU^T=\XG8/153D.B.MNS-]=.[J[PS'8N%PF3J=]=:T60IM[5&TNK6PM;D,_L
MO;V^J!]M39";*4-;)E(:AX*":CA%5)[KW1;]K?S/L5O[L;XM]=[2ZXV3CLC\
MF/CGT5\D:"#M'Y#[(ZQW%1;<[QS^X<-1[4V'M+)8'*9/M[>FUJ?:]54UE)C&
MI]0>!%8&8$>Z]TMNO?YE76_8&_LSU?#L#>6`WU@OF+N+XHU6"SL^.IY,EA<;
M7=S8K;O?^VZB,R09[J[=N>Z,S^*C\96KH\QCZNDJ%1Z>\GNO=1(/Y@.[9/CE
MVW\Q:GXWY+'?&+9W2/9G>76>]*_M3;4&].T-L;#A:OV]497K\X,IUYA^T<!!
M+EL-62Y3)208T(^1IZ&>04X]U[HQO1GR3H>S^BLYWQO)>KMK[2P!W=D:W-=7
M=V;>^06QAM39E#]WFL^N_MEX3%8N6HQTE+6155#%#+-3-2$%F9M*^Z]T6;</
M\P+L/97Q=W7\N]__`!@_N)U&VUNJ]X]62;G[TV309W<>%[>[`VQLK:[]JP?P
M)\)TO+2XO>-!F\BYK\_2X^@:5)YTJ87A]^Z]TZ_\.+[<VUE/B+0=D[&Q%!AO
MEED^SL;C^R^I.U=M=X=.]=KLO<FQ=F;,S&YNP]NXO#4M?MSLS>W8N)P-/D*6
MF-+C,Y74]-5NJR&9/=>Z:,C\^^ULI2?%7,=6?%:'?.!^659F-N[+K<YWI@]B
MU^W]Z[;VIVMO[<&!W'BZC8F>TXZDV9U-65$-?!-()ZJHBIS#'9I![KW7>WOY
MD%!N/L[Y8[)H>O\`8SX;XDQ]SG>447R#V94=T9?_`$-;3PVY*W*TO046!.Y\
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MJSM[$;QVW78YI*>7`97`]J4B0-K?R^%I%8HZ^_=>Z*UC?YB^S<GBOG#E8.M]
MS)!\/=E;_P"RMLM/G,#%!\C.O>MZ7L+`[FW9US5,_AQ>.HNX>H]S;3D:LU+'
M+0TU<S?:U],3[KW7+9?\P*G[EP59-T3U!E]X[UH.A]O=T9'8>^-VT?6&3V[F
M6[.W;U;V5T_O*IJ\%N.3;'9'4^?V/DXLE#)3RT\]1`(H9-$D<[>Z]TR[(^>G
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M7O?NO=>]^Z]UK=2_Q?\`V:.'5_I#_P!%?_#O@T^?^X_^R4?Z5?X.VG[7P_\`
M.9?^S"ZO]5_QAC_27KOZ??NO=6K_`!5T?[,Q_,LT^+5_LT/4OD\?GUZO]D>^
M*MO/Y?V_)HM;Q^G3:_JU>_=>ZK[[6\/\$^;U_P"YUO\`AXWX,:_N_O?[Q^7^
M\_\`+1T?;Z/5Y/T^/1^SHOJ_M^_=>Z"/!?Z2_P#0G_->^Y_V9#_11_?K^9GX
M_P"`?[*7_H6^Z_TL[N_BWVG\*_YS3^_\7WO\6\O^1_:??_PW]S^$^_=>Z)?U
MWY/[A_*S^Y'^RE_Q3[C^49]K_P`-0?:?Z&?X[_L\&U/[L_>?[,)_OS_]F:^X
M\_\`=7[W_?N_W4^R_C_[/V?OW7NKV-Z_WF_T^?RI_P"^_P#I&_O9_?OY*?Q?
M_3/_`*)/]*7WG^RP]IZO[U?[+U_QA3^+>#3?^!_Y!X-.G][7[]U[HFV-\/\`
M=S9O_'KV_P"'].RK:/O_`.->;_9ANW+Z_P"U][JO]?V/#>WIM[]U[H8?YS?]
M_/\`0?N7^&_Z6O\`1I_=O:/^D?[[_9;O]E2_@_\`I+Q7W_\`I3_O9_SEK_>S
M^&Z_LO\`13_N=_X#_9_Y=XO?NO=.GQ@_OI_LPGR/_NQ_LQ/^BS_9NOD1_>O_
M`$3_`.@+_9+?[Y?9Y#^)?W@_TO\`_.9']]?+]I_?7^YG^_#_`-(WWWV/[?\`
M$O?NO=$K^'O^DG_2I\$?]'?^FW^&_P##2W\NW^^'^A/_`&5#^%_P3_2+W%X_
M](?^S2?[^O\`NG]O]UI_N+_OX?#]SK_?^P]^Z]UBS/\``_\`9O?Y;'F_T?\`
M\8_X<D_F<?P?^'?Z0_\`2W]O_I]^4_\`&?XG]A_OQ?\`01?P>?\`CO\`E7]]
M/X7_``OC[OW[KW7L3_?;_AJ?Y,^#_9DO]$/^R.?);^X/G_V7S_9*ON/LLE?_
M`&6S^)?\YQ_Z._O?N?\`1_\`Z2_\E_NSIM_DOV/OW7NKC.H_](?^RI]L?Z5_
M[[_QS^"]E:?]F]_V5S^$?P;^YR^'^]7^R6_\8[_T4^7S??ZO]SWB^\\O[?VW
MOW7NJ>=Q_P"DS_AK2H_[+4_NE_</X2_Z'?\`2I_LI'^CK[3_`&9;H7^[O^R^
MW_XS=J^W^T_NS_IV_P`M_A'VG\;_`'OXC[]U[HQW?/\`>G^"["_TO>7^,?[)
M1_,N_C/^SR_Z&_[O_P`#_O9\3+_Z3?\`9&_]^-_<#^'_`*/X#_OXO\U;_+;^
M_=>Z;OA]]I_LM7\A?[7^,_;?WVW=]C_>W^-_WN\'^R2?+CP_WD_B_P#N7_O7
MX/\`BY?Q#_*/NO-Y?WO?NO=(79'^DGR?S:_'_IS_`-%?^D3Y\_<_8_[*?_LO
M_P#&?]"^WM7\0^[_`.<R_P"\_P!W?R?:?[@?NO%I_P`FM[]U[H</Y*NC^Y'>
M_P!G_HZ^R_CW3/W_`/LM_G_V5C^\7^@O9'W7]WOX[_N>_P!F3_N[_"_]*?\`
M#?\`?K?Q'^'?;_[F_P"\/OW7NB._+G^^W]_/F/\`Z4_])?VW_#?F[_[K_P"S
M7_[+Y_'?[C?[-1U-_>G^_7^R;_[E?]DE^S^R_OQ_?#_C(O\`<[^(_P!WO\I_
MBOOW7NL7Q:_AG]Z]Y_P__94/MO\`AP3^7E]Q_LB/][?]E*_B_P#`\YK^R_O1
M_N5_V9#^&_:_WM^U_P!P?]UO[I:?\N_B'OW7NCP?R9OL?]EG^97]UOX'H_V<
MSO7[7_0#_>'_`$?_`,8_T4]/_??[+E_ID_>_T<?QGR_W/^\_W!?8?;?:?[B_
M![]U[JESX]?P7_1UVA_`_P#9*_\`MTC\Z/XA_LFO]_\`_2]_"/[JX'R_\.$?
MZ0^?[P?Q/[75_#/]SG^D?^+^/_<?]_[]U[JX/XT_P?\`X=$_F1?8_P!P_P")
M?[*IT%_'/]'W]^OX?]Q]OO/[+_2%_>/_`'ZO^G?^'>/^\O\`=W_)OX/_``#[
MO_+O-[]U[I,TW\=_T(_R5?[@_P"DS_2+_LHG^_1_V6K_`$=?[,;]C_LNG2']
MY/[N_P"S*_\`.+'^@W^%6_O;_??_`'(_QC^[/\"_W(ZO?NO=!#2?P7_1;B?X
MC_HP^S_V5C^<O_>;_9F/[_?9_?\`^SC?&K^^W^S8_P!U?]SO^F?^-?=_WP_N
MC_N-_O/H_NI_N*_AWOW7NB]=9_W>_P!DVZT_BG\,_@/_``RYL+S_`.DW_2A_
M>7^&_P"S3X?Q?\>=_P`9(_TT_I_@'VW^Y7^^_P!GY/[?OW7NK>_AK_>__9Q^
MVO\`27_IV_O_`/[+-U3K_P!G"_T&_P"G[^Z?]_\`?7\$_P!'G^RE?\XS?Z'_
C`.)??_QKQ_[_`&_O)X?XM_D'\(]^Z]U;?[]U[KWOW7NO_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
